



Paxlovid – COVID-19

Guidance for treatment – high risk patients (interim)

Some key criteria for severely immunocompromised


1. Rituximab or other B-cell or T-cell depleting therapy in the previous 12 months
2. 40mg prednisolone or more per day, for 1 week or longer in the past 3 months
3. 20mg prednisolone or more per day, for 2 weeks or longer in the past 3 months
4. solid organ transplant in the previous 12 months
5. lung transplant at any time
6. haematopoietic stem cell transplant in the last 12 months
7. untreated HIV with CD4 count less than 50
8. severe combined immunodeficiency (SCID)
9. Active graft versus host disease (GVHD)

[Click here for Full Clinical Prioritisation Framework for the Use and Prescribing of Emerging Novel Therapeutics for Covid-19](#)

This guide applies to patients:

- within 5 days of the onset of Covid-19 symptoms
- Covid-19 confirmed with a positive PCR test (or other high specificity method approved by hospital laboratory director)
 - 18 years or older
- not requiring supplemental oxygen

and should only be used by healthcare professionals with access to full applicable information



Some key high risk conditions are

1. obesity (BMI over 35)
2. diabetes mellitus
3. hypertension
4. cardiovascular disease
5. chronic lung disease
6. long term prednisolone more than 5mg/day
7. chronic leukaemia
8. myeloma
9. radiotherapy in the last 6 months
10. chemotherapy for haematology cancer in the past year
11. chemotherapy for solid cancer in the past 3 months
12. chronic kidney disease stage 4 or 5
13. liver cirrhosis (Childs C)
14. chronic neurological disease on immune based therapy

[Click here for Full Clinical Prioritisation Framework for the Use and Prescribing of Emerging Novel Therapeutics for Covid-19](#)